{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T06:15:37Z","timestamp":1794809737522,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Deregulation of FGF19-FGFR4 signaling is found in several cancers, including hepatocellular carcinoma (HCC), nominating it for therapeutic targeting. FGF401 is a potent, selective FGFR4 inhibitor with antitumor activity in preclinical models. This study was designed to determine the recommended phase 2 dose (RP2D), characterize PK\/PD, and evaluate the safety and efficacy of FGF401 alone and combined with the anti-PD-1 antibody, spartalizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with HCC or other FGFR4\/KLB expressing tumors were enrolled. Dose-escalation was guided by a Bayesian model. Phase 2 dose-expansion enrolled patients with HCC from Asian countries (group1), non-Asian countries (group2), and patients with other solid tumors expressing FGFR4 and KLB (group3). FGF401 and spartalizumab combination was evaluated in patients with HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy-four patients were treated in the phase I with single-agent FGF401 at 50 to 150\u2009mg. FGF401 displayed favorable PK characteristics and no food effect when dosed with low-fat meals. The RP2D was established as 120\u2009mg qd. Six of 70 patients experienced grade 3 dose-limiting toxicities: increase in transaminases (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094) or blood bilirubin (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092). In phase 2, 30 patients in group 1, 36 in group 2, and 20 in group 3 received FGF401. In total, 8 patients experienced objective responses (1 CR, 7 PR; 4 each in phase I and phase II, respectively). Frequent adverse events (AEs) were diarrhea (73.8%), increased AST (47.5%), and ALT (43.8%). Increase in levels of C4, total bile acid, and circulating FGF19, confirmed effective FGFR4 inhibition.\n                    <\/jats:p>\n                    <jats:p>Twelve patients received FGF401 plus spartalizumab. RP2D was established as FGF401 120\u2009mg qd and spartalizumab 300\u2009mg Q3W; 2 patients reported PR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>At biologically active doses, FGF401 alone or combined with spartalizumab was safe in patients with FGFR4\/KLB-positive tumors including HCC. Preliminary clinical efficacy was observed. Further clinical evaluation of FGF401 using a refined biomarker strategy is warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02325739\">NCT02325739<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-022-02383-5","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:05:48Z","timestamp":1654128348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["A first-in-human phase 1\/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors"],"prefix":"10.1186","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-5480","authenticated-orcid":false,"given":"Stephen L.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Koo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jui","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Edeline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Pin","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Heinz","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Macarulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Cattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Frederic","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Maur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Pant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Assenat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew X.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Yeong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Bruix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Geier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Guill\u00e9n-Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Fasolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shukui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Riester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Katsanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Kakizume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Graus","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Delord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"issue":"6","key":"2383_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"2383_CR2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450\u201362.","journal-title":"N Engl J Med"},{"issue":"3","key":"2383_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol"},{"issue":"1","key":"2383_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236.","journal-title":"J Hepatol"},{"issue":"4","key":"2383_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390.","journal-title":"N Engl J Med"},{"issue":"10126","key":"2383_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet."},{"issue":"7","key":"2383_CR7","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940\u201352.","journal-title":"Lancet Oncol."},{"issue":"10088","key":"2383_CR8","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492\u2013502.","journal-title":"Lancet"},{"key":"2383_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.annonc.2021.10.008","volume":"33","author":"RK Kelley","year":"2022","unstructured":"Kelley RK, Yau T, Cheng A-L, Kaseb A, Qin S, Zhu AX, et al. Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial. Ann Oncol. 2022;33:114\u20136.","journal-title":"Ann Oncol"},{"issue":"26","key":"2383_CR10","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, et al. Phase 1b study of Lenvatinib plus Pembrolizumab in Patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960\u201370.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2383_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","volume":"18","author":"B Sangro","year":"2021","unstructured":"Sangro B, Sarobe P, Herv\u00e1s-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525\u201343.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"20","key":"2383_CR12","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"1","key":"2383_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","volume":"22","author":"T Helsetn","year":"2016","unstructured":"Helsetn T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res. 2016;22(1):259\u201367.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2383_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jhep.2008.08.015","volume":"50","author":"HK Ho","year":"2009","unstructured":"Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol. 2009;50(1):118\u201327.","journal-title":"J Hepatol"},{"issue":"3","key":"2383_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ccr.2011.01.040","volume":"19","author":"ET Sawey","year":"2011","unstructured":"Sawey ET, Chanrion M, Cai C, Wu G, Zhang J, Zender L, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell. 2011;19(3):347\u201358.","journal-title":"Cancer Cell"},{"issue":"6","key":"2383_CR16","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3390\/cells8060536","volume":"8","author":"A Raja","year":"2019","unstructured":"Raja A, Park I, Haq F, Ahn SM. FGF19-FGFR4 Signaling in hepatocellular carcinoma. Cells. 2019;8(6):536.","journal-title":"Cells."},{"issue":"1","key":"2383_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000488541","volume":"8","author":"HJ Kang","year":"2019","unstructured":"Kang HJ, Haq F, Sung CO, Choi J, Hong SM, Eo SH, et al. Characterization of hepatocellular carcinoma patients with FGF19 amplification assessed by fluorescence in situ hybridization: a large cohort study. Liver Cancer. 2019;8(1):12\u201323.","journal-title":"Liver Cancer"},{"key":"2383_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1476-4598-11-14","volume":"11","author":"W Poh","year":"2012","unstructured":"Poh W, Wong W, Ong H, Aung MO, Lim SG, Chua BT, et al. Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. Mol Cancer. 2012;11:14.","journal-title":"Mol Cancer"},{"issue":"12","key":"2383_CR19","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","volume":"9","author":"RD Kim","year":"2019","unstructured":"Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, et al. First-in- human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Cancer Discov. 2019;9(12):1696\u2013707.","journal-title":"Cancer Discov."},{"issue":"6","key":"2383_CR20","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/S0002-9440(10)61177-7","volume":"160","author":"K Nicholes","year":"2002","unstructured":"Nicholes K, Guillet S, Tomlinson E, Hillan K, Wright B, Frantz GD, et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol. 2002;160(6):2295\u2013307.","journal-title":"Am J Pathol"},{"issue":"42","key":"2383_CR21","doi-asserted-by":"publisher","first-page":"5890","DOI":"10.1039\/C9CC02052G","volume":"55","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Chen X, Fu Y, Zhang Y, Dai S, Li J, et al. Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4. Chem Commun (Camb). 2019;55(42):5890\u20133.","journal-title":"Chem Commun (Camb)"},{"issue":"12","key":"2383_CR22","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1158\/1535-7163.MCT-18-1291","volume":"18","author":"A Weiss","year":"2019","unstructured":"Weiss A, Adler F, Buhles A, Stamm C, Fairhurst RA, Kiffe M, et al. FGF401, A first-in-class highly selective and potent FGFR4 inhibitor for the treatment of FGF19-driven hepatocellular cancer. Mol Cancer Ther. 2019;18(12):2194\u2013206.","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"2383_CR23","doi-asserted-by":"publisher","first-page":"12542","DOI":"10.1021\/acs.jmedchem.0c01019","volume":"63","author":"RA Fairhurst","year":"2020","unstructured":"Fairhurst RA, Knoepfel T, Buschmann N, Leblanc C, Mah R, Todorov M, et al. Discovery of roblitinib (FGF401) as a reversible-covalent inhibitor of the kinase activity of fibroblast growth factor receptor 4. J Med Chem. 2020;63(21):12542\u201373.","journal-title":"J Med Chem"},{"key":"2383_CR24","doi-asserted-by":"publisher","unstructured":"Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang R, et al. Lenvatinib targets fgf receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC. Hepatology. 2021. https:\/\/doi.org\/10.1002\/hep.31921 Epub ahead of print.","DOI":"10.1002\/hep.31921"},{"key":"2383_CR25","doi-asserted-by":"crossref","unstructured":"Naing A, Gainor JF, Gelderblom H, Forde PM, Butler MO, Lin CC, et al. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. J Immunother Cancer. 2020;8(1).","DOI":"10.1136\/jitc-2020-000530"},{"issue":"1","key":"2383_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25\u201334.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2383_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15\u201321.","journal-title":"Bioinformatics."},{"issue":"2","key":"2383_CR28","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31(2):166\u20139.","journal-title":"Bioinformatics."},{"issue":"1","key":"2383_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139\u201340.","journal-title":"Bioinformatics."},{"key":"2383_CR30","doi-asserted-by":"publisher","first-page":"viii413","DOI":"10.1093\/annonc\/mdy288.032","volume":"29","author":"CC Lin","year":"2018","unstructured":"Lin CC, Taylor M, Boni V, Brunsvig PF, Geater SL, Salvagni S, et al. Phase I\/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer. Ann Oncol. 2018;29:viii413.","journal-title":"Ann Oncol"},{"issue":"4","key":"2383_CR31","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","volume":"175","author":"L Jerby-Arnon","year":"2018","unstructured":"Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, et al. A cancer cell program promotes t cell exclusion and resistance to checkpoint blockade. Cell. 2018;175(4):984\u201397.e24.","journal-title":"Cell."},{"key":"2383_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7. https:\/\/doi.org\/10.1186\/1471-2105-14-7.","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"2383_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0040-1722261","volume":"41","author":"R Dhanasekaran","year":"2021","unstructured":"Dhanasekaran R. Deciphering tumor Heterogeneity in Hepatocellular Carcinoma (HCC)\u2014multi-omic and singulomic approaches. Semin Liver Dis. 2021;41(1):9\u201318. https:\/\/doi.org\/10.1055\/s-0040-1722261.","journal-title":"Semin Liver Dis"},{"issue":"1","key":"2383_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2019.02.015","volume":"513","author":"T Hoshi","year":"2019","unstructured":"Hoshi T, Watanabe Miyano S, Watanabe H, Sonobe RMK, Seki Y, Ohta E, et al. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades. Biochem Biophys Res Commun. 2019;513(1):1\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"2383_CR35","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/cam4.1517","volume":"7","author":"M Matsuki","year":"2018","unstructured":"Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y, Funahashi Y, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018;7(6):2641\u201353.","journal-title":"Cancer Med"},{"issue":"13","key":"2383_CR36","first-page":"Supplement","volume":"77","author":"SL Chan","year":"2017","unstructured":"Chan SL, Yen CJ, Schuler M, Lin CC, Choo SP, Weiss KH, et al. Abstract CT106: Ph I\/II study of FGF401 in adult pts with HCC or solid tumors characterized by FGFR4\/KLB expression. Cancer Res. 2017;77(13):Supplement.","journal-title":"Cancer Res"},{"issue":"5","key":"2383_CR37","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1007\/s12072-021-10212-8","volume":"15","author":"DWM Tai","year":"2021","unstructured":"Tai DWM, Le TBU, Prawira A, Ho RZW, Huynh H. Targeted inhibition of FGF19\/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma. Hepatol Int. 2021;15(5):1236\u201346.","journal-title":"Hepatol Int"},{"issue":"4","key":"2383_CR38","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1158\/2159-8290.CD-14-1029","volume":"5","author":"M Hagel","year":"2015","unstructured":"Hagel M, Miduturu C, Sheets M, Rubin N, Weng W, Stransky N, et al. First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway. Cancer Discov. 2015;5(4):424\u201337.","journal-title":"Cancer Discov"},{"key":"2383_CR39","unstructured":"Bifulco N JR., DiPietro LV, Miduturu CV (inventor); Blueprint Medicines Corp (assignee). Inhibitors of the fibroblast growth factor receptor. US9695165B2. Unites States;\u00a02017."},{"issue":"24","key":"2383_CR40","doi-asserted-by":"publisher","first-page":"6999","DOI":"10.1158\/0008-5472.CAN-17-1865","volume":"77","author":"JJ Joshi","year":"2017","unstructured":"Joshi JJ, Coffey H, Corcoran E, Tsai J, Huang CL, Ichikawa K, et al. H3B-6527 is a potent and selective inhibitor of FGFR4 in FGF19-driven hepatocellular carcinoma. Cancer Res. 2017;77(24):6999\u20137013.","journal-title":"Cancer Res"},{"issue":"15","key":"2383_CR41","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1200\/JCO.2019.37.15_suppl.4095","volume":"37","author":"TM Mercade","year":"2019","unstructured":"Mercade TM, Moreno V, John B, Morris JC, Sawyer MB, Yong WP, et al. A phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) patients. J Clin Oncol. 2019;37(15):4095.","journal-title":"J Clin Oncol"},{"issue":"15","key":"2383_CR42","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.1200\/JCO.2021.39.15_suppl.4090","volume":"39","author":"T Macarulla","year":"2021","unstructured":"Macarulla T, Moreno V, Li-T C, Sawyer MB, Goyal L, Mart\u00edn AJM, et al. Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC). J Clin Oncol. 2021;39(15):4090.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2383_CR43","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2019.08.014","volume":"72","author":"J Hou","year":"2020","unstructured":"Hou J, Zhang H, Sun B, Karin M. The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications. J Hepatol. 2020;72(1):167\u201382.","journal-title":"J Hepatol"},{"key":"2383_CR44","doi-asserted-by":"crossref","unstructured":"Kelley RK YT, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma: Results from the randomized phase III COSMIC-312 trial. ESMO Presented Nov 20, 2021; virtual plenary. 2021.","DOI":"10.1016\/j.annonc.2021.10.008"},{"issue":"4_suppl","key":"2383_CR45","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1200\/JCO.2022.40.4_suppl.379","volume":"40","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Chan SL, Kudo M, Lau G, Kelley RK, Furuse J, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol. 2022;40(4_suppl):379.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02383-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-022-02383-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02383-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:06:16Z","timestamp":1654128376000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-022-02383-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2383"],"URL":"https:\/\/doi.org\/10.1186\/s13046-022-02383-5","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]},"assertion":[{"value":"7 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol and all amendments were reviewed by the independent ethics committee or institutional review board for each center. The study was conducted according to ICH E6 Guideline for Good Clinical Practice that have their origin in the Declaration of Helsinki. Informed consent was obtained from each patient in writing before any study-specific procedure was performed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors give consent for the publication of the manuscript in Journal of Experimental & Clinical Cancer Research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S. L. Chan: Research fund from Bayer, Eisai, Ipsen, MSD, Sirtex; advisors for AstraZeneca, BMS, Eisai, Novartis, MSD.M. Schuler: Consultant (compensated) for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Novartis, Roche, Takeda; honoraria for CME presentations from Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, MSD, Novartis; research funding to institution from AstraZeneca, Boehringer Ingelheim, Bristol Myers-Squibb, Novartis.Y.-K Kang: Consulting fee from ALX Oncology, Amgen, Blueprint, BMS, Daehwa, MacroGenics, Merck, Novartis, Roche, Surface Oncology, Zymeworks.C.-J Yen: No conflicts of interest to declare.J. Edeline: Consultancy\/honoraria from AstraZeneca, Bayer, BMS, Boston Scientific, Eisai, Ipsen, MSD, Roche; grant funding from BeiGene, BMS, Boston Scientific.S.P. Choo: Consultancy\/honoraria from Bayer, BMS, Eisai, Ipsen, MSD, Roche; Speaker fees from BMS, Eisai, Eli Lilly, Roche, Sirtex; grant funding from BMS, Sirtex.C.-C. Lin: Consulting fee from AbbVie, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Novartis; honoraria from Eli Lilly, Novartis, Roche; support for attending meeting or travel from BeiGene, Daiichi Sankyo, and Eli Lilly.T. Okusaka: Grant and honoraria from Novartis.K.-H. Weiss: grants from Alexion, Novartis, Orphalan, Univar; consulting fee from Alexion, Bayer, Chiesi, Orphalan, Pfizer, Ultragenyx, Univar, Vivet therapeutics; honoraria from Falk; support for attending meeting from AbbVie, Bayer, Gilead.T. Macarulla: Consultancy\/advisory role with Amgen, Baxter, Celgene, Incyte, Q&D Therapeutics, Servier, Shire; research funding from AstraZeneca, BeiGene, Celgene.S. Cattan: grants, consulting fee and honoraria from AstraZeneca, Bayer, Ipsen, Roche; payment for expert testimony and support for travel from AstraZeneca, Ipsen, Roche; participation in advisory board for Roche.J.-F. Blanc: honoraria from Bayer, Ipsen, Roche; support for attending meeting\/travel from Bayer and Ipsen; participation in safety\/advisory board for AstraZeneca, Bayer, BMS, Eisai, Ipsen, Eli Lilly, MSD, Roche.K.-H Lee: honoraria from AstraZeneca and Roche; participated in advisory board for Surface Oncology.M. Maur: No conflicts of interest to declare.S. Pant: Consulting or advisory role for 4D Pharma, Ipsen, Xencor, Zymeworks; research funding from 4D Pharma, Arcus Biosciences, ArQule, Astellas Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Elicio Therapeutics, Five Prime Therapeutics, GlaxoSmithKline, Ipsen, Janssen, Lilly, Mirati Therapeutics, NGM Biopharmaceuticals, Novartis, Onco Response, Purple Biotech, RedHill Biopharma, Rgenix, Sanofi\/Aventis, Xencor.M. Kudo: Consulting fee from BMS, Eisai, MSD, Ono Pharmaceuticals, Roche; honoraria from Bayer, BMS, Chugai, EA Pharma, Eisai, Eli Lilly, MSD; Research funding from AbbVie, Chugai, Eisai, EA Pharma, Gilead Sciences, Ono Pharmaceutical Co, Otsuka, Sumitomo Dainippon Pharma, Taiho, Takeda.E. Assenat: No conflicts of interest to declare.A.X. Zhu: Consulting fee from Bayer, BMS, Eisai, Eli Lilly, Exelixis, Roche, Sanofi.T. Yau: Consulting or advisory role and honoraria from AbbVie, AstraZeneca, Bayer, Bristol Myers-Squibb, Eisai, Eli Lilly, EMD Serono, Exelixis, H3 Biomedicine, Ipsen, MSD, New B Innovation, Novartis, OrigiMed, Pfizer, SillaJen, Sirtex, Taiho.H.Y. Lim: Participation on data safety monitoring committee or advisory board from Bayer, BMS, Eisai, Merck Serono and Roche.J. Bruix: Consultancy from AbbVie, Adaptimmune, ArQule, Astra-Medimmune, Basilea, Bayer Shering Pharma, Bio-Alliance, BMS, BTG, Eisai, Gilead, Incyte, Ipsen, Kowa, Lilly, MSD, Nerviano, Novartis, Polaris, Quirem, Roche, Sirtex, Sanofi, Terumo; Research grants from Bayer, Ipsen; Educational grants from Bayer; Paid conferences from Bayer, BTG and Ipsen; Paid talks for Bayer Shering Pharma, BTG Biocompatibles, Eisai, Ipsen Sirtex, Terumo.A. Geier: Advisor and Steering Committee member for AbbVie, Alexion, Bayer, BMS, Eisai, Gilead, Intercept, Ipsen, Novartis, Pfizer, Roche, Sanofi-Aventis, Sequana; Speaker fees from AbbVie, Alexion, BMS, CSL Behring, Falk, Gilead, Intercept, Merz, Novartis, Roche, Sequana; Research support from Intercept and Falk (NAFLD CSG), Novartis.C. Guill\u00e9n-Ponce: Registration for continuing education courses and congresses by Astra Zeneca, Merck Serono and Sanofi.A. Fasolo: No conflicts of interest to declare.R.S. Finn: Grants from Adaptimmune, Bayer, BMS, Eisai, Eli Lilly, Merck, Pfizer, Roche\/Genentech; consulting fee from Adaptimmune, AstraZeneca, Bayer, BMS, CStone, Eisai, Eli Lilly, Merck, Pfizer, Roche\/ Genentech.J. Fan: No conflicts of interest to declare.A. Vogel: consulting fee from Amgen, AstraZeneca, Bayer, BMS, BTG, EISAI, GSK, Incyte, Ipsen, Lilly, Merck, PierreFabre, MSD, Novartis, Roche, Sanofi, Servier, Sirtex, Terumo,; honoraria from Amgen, AstraZeneca, Bayer, BMS, BTG, EISAI, GSK, Incyte, Ipsen, Lilly, Merck, MSD, Novartis, PierreFabre, Roche, Sanofi, Servier, Sirtex, Terumo.S. Qin: No conflicts of interest to declare.M. Riester: Novartis employee.V. Katsanou: Novartis employee.M. Chaudhari: worked for Novartis during employment at IQVIA.T. Kakizume: Novartis employee at the time of study and manuscript writing; currently working at Takeda.Yi Gu: Novartis employee and stock holder.D. Graus Porta: Novartis employee and stockholder at the time of study conduct and manuscript finalization.A. Myers: Novartis employee.J-P. Delord: Consulting fee from BMS, MSD, Roche; honoraria from Roche; participation on data safety monitoring board or advisory board for BMS, MSD, Novartis, Transgene.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"189"}}